ClinicalTrials.gov record

Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

ClinicalTrials.gov ID: NCT00661674

Public ClinicalTrials.gov record NCT00661674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).

Study identification

NCT ID: NCT00661674
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Stanford University; Other
Enrollment: 10 participants

Conditions and interventions

Conditions

Substance-Related Disorders

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 35 Years
Sex: Male
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2008
Primary completion: Jul 31, 2008
Completion: Jul 31, 2008
Last update posted: Jun 4, 2017

2008

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Stanford University School of Medicine	Stanford	California	94305	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00661674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 4, 2017 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00661674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →